Tumour‐derived exosomes as antigen delivery carriers in dendritic cell‐based immunotherapy for malignant mesothelioma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: In 2001, it was postulated that tumour‐derived exosomes could be a potent source of tumour‐associated antigens (TAA). Since then, much knowledge is gained on their role in tumorigenesis but only very recently tumour‐derived exosomes were used in dendritic cell (DC)‐based immunotherapy. For this, DCs were cultured ex‐vivo and loaded with exosomes derived from immunogenic tumours such as melanoma or glioma and re‐administrated to induce anti‐tumour responses in primary and metastatic tumour mouse models. In contrast, malignant mesothelioma (MM) is a non‐immunogenic tumour and because only a few mesothelioma‐specific TAA are known to date, we investigated whether mesothelioma‐derived exosomes could be used as antigen source in DC‐based immunotherapy. Methods: Mouse MM AB1 cells were used to generate tumour lysate and tumour‐derived exosomes. Tumour lysate was generated by 5 cycles of freeze–thawing followed by sonication of AB1 cells. Tumour exosomes were collected from the AB1 cell culture supernatant and followed a stepwise ultracentrifugation. Protein quantification and electron microscopy were performed to determine the protein amount and to characterise their morphology. To test whether MM derived exosomes are immunogenic and able to stimulate an anti‐tumoral response, BALB/c mice were injected with a lethal dose of AB1 tumour cells at day 0, followed by intraperitoneal injection of a single dose of DCs loaded with tumour exosomes, DCs loaded with tumour lysate, or phosphate buffered saline (PBS), at day 7. Results: Mice which received tumour exosome‐loaded DC immunotherapy had an increased median and overall survival compared to mice which received tumour lysate‐loaded DC or PBS. Conclusion: In this study, we showed that DC immunotherapy loaded with tumour exosomes derived from non‐immunogenic tumours improved survival of tumour bearing mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions
Bard, M. P., Hegmans, J. P., Hemmes, A., Luider, T. M., Willemsen, R., Severijnen, L.-A. A., van Meerbeeck, J. P., Burgers, S. A., Hoogsteden, H. C., & Lambrecht, B. N. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0238oc · Cited by 416
Self-citationKesimer, M., Scull, M., Brighton, B., DeMaria, G., Burns, K., O'Neal, W., Pickles, R. J., & Sheehan, J. K. (2009) · The FASEB Journal · doi:10.1096/fj.08-119131 · Cited by 346
Cited by
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207
Engineering exosomes as refined biological nanoplatforms for drug delivery
Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.12 · Cited by 1,163
Greening, D. W., Xu, R., Ji, H., Tauro, B. J., & Simpson, R. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2550-6_15 · Cited by 711
Zhao, Z., Yang, Y., Zeng, Y., & He, M. (2016) · Lab on a Chip · doi:10.1039/c5lc01117e · Cited by 684
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
Metadata
- Authors
- Mahaweni, N. M., Kaijen‐Lambers, M. E. H., Dekkers, J., Aerts, J. G. J. V., & Hegmans, J. P. J. J.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 2
- Issue
- 1
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W2113777630
- Cited by
- 119
- References
- 2
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour‐derived exosomes as antigen delivery carriers in dendritic cell‐based immunotherapy for malignant mesothelioma. https://app.cochat.ai/papers/10.3402/jev.v2i0.22492
- The paper
- Mahaweni, N. M., Kaijen‐Lambers, M. E. H., Dekkers, J., Aerts, J. G. J. V., & Hegmans, J. P. J. J. (2013). Tumour‐derived exosomes as antigen delivery carriers in dendritic cell‐based immunotherapy for malignant mesothelioma. Journal of Extracellular Vesicles. https://doi.org/10.3402/jev.v2i0.22492
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.